Sanofi appoints specialty care head; Biogen chair to retire in Junenews2026-02-20T12:00:30+00:00February 20th, 2026|Endpoints News|
Grail’s cancer test misses primary study goal in UK studynews2026-02-20T03:19:15+00:00February 20th, 2026|Endpoints News|
AbbVie, PhRMA can proceed with 340B case in Hawaiinews2026-02-19T19:35:39+00:00February 19th, 2026|Endpoints News|
When a health tech startup gets stuck in regulatory limbonews2026-02-19T19:16:19+00:00February 19th, 2026|Endpoints News|
Teva beats Corcept in appeals fight over generic Cushing’s syndrome drugnews2026-02-19T19:08:40+00:00February 19th, 2026|Endpoints News|
FDA formalizes one pivotal trial policy via NEJM perspectivenews2026-02-19T16:47:54+00:00February 19th, 2026|Endpoints News|
Obesity biotech Verdiva plans big year of data, explores dealsnews2026-02-19T16:47:40+00:00February 19th, 2026|Endpoints News|
Biogen stops part of an MS trial; Merck reports more Enflonsia datanews2026-02-19T15:55:48+00:00February 19th, 2026|Endpoints News|
Sanofi to expand in India; Stada invests $100M in Saudi Arabianews2026-02-19T15:42:43+00:00February 19th, 2026|Endpoints News|
Hims to buy Australia’s Eucalyptus for $240M upfront in global pushnews2026-02-19T14:52:28+00:00February 19th, 2026|Endpoints News|
